Invention Grant
US09562232B2 Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (miR145) and micro-RNA 212 (miR212)
有权
通过微RNA 132（miR132），微RNA 145（miR145）和微RNA 212（miR212）调节人巨细胞病毒复制，
- Patent Title: Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (miR145) and micro-RNA 212 (miR212)
- Patent Title (中): 通过微RNA 132（miR132），微RNA 145（miR145）和微RNA 212（miR212）调节人巨细胞病毒复制，
-
Application No.: US14563512Application Date: 2014-12-08
-
Publication No.: US09562232B2Publication Date: 2017-02-07
- Inventor: Timothy F. Kowalik , Mariluz Rodriguez-Gonzalez , Alexander Lagadinos
- Applicant: University of Massachusetts
- Applicant Address: US MA Boston
- Assignee: University of Massachusetts
- Current Assignee: University of Massachusetts
- Current Assignee Address: US MA Boston
- Agency: McCarter & English, LLP
- Agent Jill Ann Mello, Esq.; Briana M. Erickson, Esq.
- Main IPC: C12N15/11
- IPC: C12N15/11 ; C12N15/113 ; A61K31/522 ; A61K31/7105 ; A61K35/50 ; A61K45/06 ; C12Q1/70
Abstract:
The present invention related to miR145, miR132, miR212, and the genes or gene products regulated by these miRNAs. miR145 is downregulated in cells infected with HCMV. This downregulation modulates expression of miR145 target genes, including IRS-1. Transfection of cells with a miR145 agent, such as a miR145 mimetic, reduces HCMV replication and protein expression. miR132 and miR212 are upregulated in cells infected with HCMV. This upregulation modulates expression of miR132 and miR212 target genes, including MeCP2 and RICS. Transfection of cells with a miR132 and/or a miR212 antagonist reduces HCMV replication and protein expression. Accordingly, the invention provides methods of attenuating HCMV replication by modulating, for example, miR145, miR132, and/or miR212, and targets thereof. Also provided are methods of detecting an HCMV infection, and compositions and kits useful for attenuating HCMV replication.
Public/Granted literature
Information query
IPC分类:
